# An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

> **NCT03094429** · PHASE2,PHASE3 · RECRUITING · sponsor: **SyneuRx International (Taiwan) Corp** · enrollment: 287 (estimated)

## Conditions studied

- Refractory Schizophrenia

## Interventions

- **DRUG:** NaBen®
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03094429
- **Lead sponsor:** SyneuRx International (Taiwan) Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-03-29
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 287 (ESTIMATED)
- **Last updated:** 2021-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03094429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03094429, "An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03094429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*